Eli Lilly and Co

Change company Symbol lookup

Select an option...

LLY Eli Lilly and Co

ESTC Elastic NV

STKH Steakholder Foods Ltd

NHEL Natural Health Farm Holdings Inc

ICPT Intercept Pharmaceuticals Inc

BMY Bristol-Myers Squibb Co

DTCFF Defence Therapeutics Inc

ADBE Adobe Inc

FATP Fat Projects Acquisition Corp

LGVC LAMF Global Ventures I Corp

Go

This article was automatically generated by MarketWatch using technology from Automated Insights. Shares of Eli Lilly & Co. (LLY) inched 0.32% higher to $552.29 Monday, on what proved to be an all-around positive trading session for...(MarketWatch)

Following the latest approval, Lilly's (LLY) Jardiance can access a target market that affects more than 35 million adults in the United States.(Zacks)

Zacks.com users have recently been watching Lilly (LLY) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.(Zacks)

Sector ETF report for PJP(Zacks)

This article was automatically generated by MarketWatch using technology from Automated Insights. Shares of Eli Lilly & Co. (LLY) inched 0.07% higher to $550.54 Friday, on what proved to be an all-around dismal trading session for...(MarketWatch)

Eli Lilly & Co. (LLY) and Boehringer Ingelheim said Friday that the U.S. Food and Drug Administration has approved their blockbuster drug Jardiance, already used for heart failure and diabetes, as a treatment for adults with chronic...(MarketWatch)

-- Approval adds to the treatment options for the more than 35 million adults in the U.S. affected by chronic kidney disease (CKD) -- Jardiance(R) (empagliflozin) 10 mg tablets significantly reduced the risk of kidney disease progression and...(PR Newswire)

Eli Lilly & Co. (LLY) is best positioned to dominate the fast-growing U.S. market for obesity drugs into the 2030s, BMO Capital Markets analysts said in a report late Thursday. Although Novo Nordisk (NVO), maker of Ozempic and Wegovy, is...(MarketWatch)

Eli Lilly, Toyota Motor, Accenture, The Walt Disney and CVS Health are part of the Zacks top Analyst Blog.(Zacks)

This article was automatically generated by MarketWatch using technology from Automated Insights. Shares of Eli Lilly & Co. (LLY) shed 3.42% to $550.13 Thursday, on what proved to be an all-around rough trading session for the stock...(MarketWatch)

Today's Research Daily features new research reports on 16 major stocks, including Eli Lilly and Company (LLY), Toyota Motor Corporation (TM) and Accenture plc (ACN).(Zacks)

This article was automatically generated by MarketWatch using technology from Automated Insights. Shares of Eli Lilly & Co. (LLY) slumped 0.93% to $569.64 Wednesday, on what proved to be an all-around rough trading session for the...(MarketWatch)

FinancialNewsMedia.com News Commentary The demand for abuse deterrent formulation technology is projected to grow due to growing misuse of drugs among the people. Growing demand for abuse deterrent formulation technology from the pharmaceutical...(PR Newswire)

Sector ETF report for IYH(Zacks)

In the latest trading session, Eli Lilly (LLY) closed at $574.96, marking a +0.64% move from the previous day.(Zacks)

This article was automatically generated by MarketWatch using technology from Automated Insights. Shares of Eli Lilly & Co. (LLY) inched 0.64% higher to $574.96 Tuesday, on what proved to be an all-around rough trading session for...(MarketWatch)

InvestorsObserver issues critical PriceWatch Alerts for PLTR, AVGO, LLY, GE, and TSM. https://mma.prnewswire.com/media/1333368/InvestorsObserver_Logo.jpg Click a link below then choose between in-depth options trade idea report or a stock score...(PR Newswire)

Pfizer (PFE) gets marketing authorization in the EU for Litfulo to treat adults and adolescent patients aged 12 years and older with severe alopecia areata.(Zacks)

This article was automatically generated by MarketWatch using technology from Automated Insights. Shares of Eli Lilly & Co. (LLY) slipped 0.76% to $571.28 Monday, on what proved to be an all-around great trading session for the...(MarketWatch)

Sector ETF report for XLV(Zacks)